Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “PLASMACYTOMA”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 433 records · Page 24Linked to original sources
PubMed1996

Plasma cells composing plasmacytoma have phenotypes different from those of myeloma cells.

We describe one relapsed case of plasmacytoma of mandibular bone. The organs of relapse were liver and bone marrow. At relapse, monoclonal gammopathy (IgG-kappa) was observed without suppression of IgA and IgM. By immunostaining, the plasma cells of both the original mandibular bone and liver were positive for the same cytoplasmic immunoglobulin light chain kappa. The proliferative plasma cells in the bone marrow had the phenotype of CD38+, CD19+, and CD56- by flow cytometry and showed the presence of the rearranged IgH gene by Southern blotting. In addition, the zone of the Ig class of the patient's serum was not so sharply defined by zone electrophoresis. These results suggest that the characteristics of plasma cells of plasmacytoma are different from those of multiple myeloma.

ADP-ribosyl Cyclase↗
PubMed1998

Primary plasmacytoma at the site of exit wounds after electrical injury.

We report a case of primary plasmacytoma occurring 12 years after electrical injury. Roentgenograms showed multiple well-circumscribed lytic lesions involving both the right and left tibial diaphyseal regions. Bone biopsy from the left tibial region showed sheets of monoclonal myeloma cells. No evidence of multiple myeloma was found. The patient was treated with local radiation to both tibias and had no evidence of recurrence 6 years later. In conclusion, we report the first case of primary plasmacytoma of both tibias that occurred after electrical injury 12 years before.

Adult↗
PubMedDate not supplied

Testicular plasmacytoma: appearance on gray-scale and power Doppler sonography.

A case of testicular plasmacytoma, a very rare neoplasm, is presented. The gray-scale and power Doppler sonographic findings are illustrated. The lesion appeared as a hypoechoic, intratesticular mass that was markedly hypervascular. When marked hypervascularity is present in a testicular mass in a patient unlikely to have orchitis on clinical grounds, plasmacytoma should be considered in the differential diagnosis.

Adult↗
PubMed1982

Endobronchial metastatic plasmacytoma.

Plasmacytomas are rare tumors and an endobronchial presentation has not been previously described. A 64-year-old white woman with metastatic involvement by plasmacytoma is presented. A review of the literature indicates the difficulty in distinguishing this lesion from benign plasma cell tumors of the lung and the prolonged follow-up often necessary to reveal metastatic behavior. Careful observation in this case led to the demonstration of metastatic lung and endobronchial lesions without the development of abnormal proteinuria or overt myeloma. The literature would suggest a key role for radiation therapy in treatment. The role of chemotherapy remains to be defined.

Bronchial Neoplasms↗
PubMed1991

Superior vena cava syndrome caused by an intrathoracic plasmacytoma.

A case of an extramedullary intrathoracic plasmacytoma causing superior vena cava syndrome is described. Review of the literature on intrathoracic plasmacytomas and superior vena cava syndrome revealed that no similar cases have been described to date. The initial presentation, management, and response to treatment are described.

Humans↗
PubMed2002

Testicular plasmacytoma: report of a case and review of the literature.

Plasmacytomas of the testis are rare neoplasias; they may occur as isolated tumors or in concomitance with generalized multiple myeloma. We report the case of a 77-year-old man with previous clinical evidence of multiple myeloma involving skin, ribs, and lungs, and initially treated with surgery, radiotherapy, and chemotherapy attaining partial response. Fourteen months after the onset, the patient presented with left testicular enlargement due to plasmacytoma. Immunohistochemical stains showed monoclonal cytoplasmic IgA-lambda in tumour cells; serum M component showed the same immunoglobulin. Following radiotherapy the tumour mass disappeared. Nonetheless, 2 months later while on chemotherapy, disease recurred with progressive increase of skeletal lesions. The patient is currently alive with disease progression 22 months after onset. On the basis of a review of the literature, the clinical significance of testicular myeloma localization is discussed.

Aged↗
PubMed2001

An unusual presentation of extramedullary plasmacytoma occurring sequentially in the testis, subcutaneous tissue, and heart.

Extramedullary plasmacytoma (EMP) is a rare neoplasm of soft tissue that usually arises in the respiratory tract, nasal cavity, sinuses, and nasopharynx. It is even more uncommon for it to arise either in the testis or heart. We report the presentation of a case where plasmacytomas were found sequentially in the testis, subcutaneous tissue, and heart. EMP usually has a good prognosis except when it involves the heart. Our patient survived for only 15 months post autologous hematopoietic stem cell transplantation.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1989

Solitary plasmacytoma of the skull revealed by a mononeuritis multiplex associated with immune complex vasculitis.

We describe a patient with solitary plasmacytoma of the skull, in whom mononeuritis multiplex was the presenting manifestation. Some features of the POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal [M] protein, skin changes), including thrombocytosis, were found. Muscle and nerve biopsies disclosed a small vessel hypersensitivity-type vasculitis and complement-fixing immune complex deposits in vessel walls. Removal of the plasmacytoma resulted in clinical improvement and clearance of the vasculitis and immune complex deposits.

Adult↗
PubMed2004

Histiocytes containing immunoglobulin crystals in the urine of a patient with IgA kappa plasmacytoma of the bladder.

Exfoliative cytology specimens from patients with plasma cell dyscrasias are rarely diagnostic, though there are reports of neoplastic plasma cells observed in pleural fluid and urine. Immunoglobulin concretions or crystals associated with neoplastic plasma cell populations have been well described. These crystals may be found within plasma cell nuclei or cytoplasm, extracellularly, or within cells of histiocytic lineage where they are presumably derived by phagocytosis. To the best of our knowledge, this is the first report of immunoglobulin crystals within histiocytes in the urine of a patient with plasmacytoma. A 61-year-old male underwent routine cystoscopy and urine collection to evaluate hematuria. The bladder biopsy demonstrated IgA kappa-producing plasmacytoma. Urine cytopsin preparations did not contain plasma cells, but there were histiocytic cells with degenerative nuclei and eccentrically located cytoplasmic spherical refractile hyaline crystals thought to be immunoglobulin crystals. This was supported by immunocytochemical staining.

Crystallization↗
PubMed1994

Fine-needle aspiration of pancreatic extramedullary plasmacytoma: possible confusion with islet cell tumor.

We report two cases of extramedullary plasmacytoma (EMP) of the pancreas, diagnosed by fine-needle aspiration (FNA). Plasmacytoma of the pancreas is a rare neoplasm with only 12 cases recorded in the literature. Because of its scarcity and the cytomorphologic similarity between plasma cells and endocrine cells, EMP of the pancreas may be confused with neuroendocrine (islet cell) tumors of the pancreas. Immunohistochemical staining for light chain and/or neuroendocrine markers will prevent diagnostic error when interpreting plasmacytoid neoplasms of any site susceptible to endocrine tumors, including the pancreas.

Adenoma, Islet Cell↗
PubMed1990

The "missing" mouse plasmacytoma (MPC) associated translocation T(15;16) occurs repeatedly in new MPC induction systems.

A reciprocal translocation between chromosomes 15 and 16 has been detected in seven murine plasmacytomas induced by a combination of pristane and Abelson virus. Six of the tumors were induced in a new, unconventional experimental system based on transfer of uninfected or Abelson virus infected bone marrow and spleen cells, respectively, into pristane treated mice. All six tumors were of donor type. The seventh tumor appeared in a conventional pristane + Abelson virus treated mouse. This tumor was unusual in carrying both the 15;16 variant translocation and the typical 12;15 translocation, in the same tumor cells. In the new 15;16 variant, the breakpoint of chromosome 15 was at the interphase of the D2/3 sub-bands, as in mouse plasmacytomas with the previously well-known typical 12;15 and variant 6;15 translocations. The breakpoint on chromosome 16 was mapped to band 16B1, corresponding to the presumed cytogenetic site of the Ig-lambda gene. In three of the seven tumors with the 15;16 translocation, the derivative chromosome 15 had undergone a duplication, a feature that has not been previously encountered in the MPC-associated 12;15 and 6;15 translocation carriers. The reciprocal derivative chromosome 16 was lost from one of the seven tumors. We postulate that the 15;16 translocation results in juxtaposition of the myc gene to lambda sequences, probably in a similar orientation as previously described for the variant 6;15 translocation.

Abelson murine leukemia virus↗
PubMedDate not supplied

Interactions between radioresistant T cells from plasmacytoma-bearing mice and radiosensitive T cells from normal mice leading to suppression.

Spleens from BALB/c mice bearing the plasmacytoma SPQC 11 contain a population of T cells capable of suppressing the production of antibodies when cultured with normal BALB/c splenocytes, but not with splenocytes from nude BALB/c mice. Inhibition was characteristically the most effective at low suppressor cell numbers using unirradiated T cells. Maximum suppression occurred when a radiosensitive population of T cells from normal mice interacted with a population of radioresistant T cells from plasmacytoma-bearing animals. Accurate characterization of the suppressor T cell activity required testing over a wide range of suppressor/indicator cell ratios. Suppressor activity was eliminated by treatment with anti-Thy 1.2 plus complement, was radioresistant and present over a full range of doses when irradiated cells were used.

Animals↗
PubMed1979

Immune suppression in BALB/c mice bearing the plasmacytoma TEPC-183: evidence for normal lymphocyte but defective macrophage function.

This paper analyses impairment of the primary immune response of mice bearing the plasmacytoma TEPC-183. Healthy animals and mice bearing the reported non-immunosuppressive tumour MOPC-104E were used as controls. The defect was shown to affect both primary IgG and IgM responses to chicken cells (CRBC) and to be related to tumour size. However, the primary immune depression could be overcome either by increasing the antigen dose or by using Freund's complete adjuvant together with antigen. Secondary responses were also depressed. This depression was more pronounced if the animals was primed after, rather than before, tumour implantation. Further studies involved the measurement of primary immune responses of immunologically deprived syngeneic mice, after they had been reconstituted with cells from normal or tumour-bearing mice. Lymphocyte reconstitution experiments were carried out in mice which had been irradiated with 950R. Various lymphoid preparations from TEPC-183-bearing mice were unable to bring about such restoration. It is concluded that the impairment of the primary immune response of mice bearing the plasmacytoma TEPC-183 is due to a macrophage, rather than a lymphocyte, abnormality. However, none of these transfer studies suggested that positive suppression of primary immune responses was being mediated by cells from TEPC-183-bearing mice.

Animals↗
PubMed1980

Effector and enhancing lymphoid cells in plasmacytoma-bearing mice. I. Methodological studies on the Winn assay.

Some parameters of the Winn assay for the detection of tumor-suppressing ("effector") and tumor-enhancing lymphoid cells were studied in BALB/c mice. Spleen cells of mice that were preimmunized with mitomycin-C-treated MOPC-104E plasmacytoma cells were inhibitory in this test system for both the MOPC-104E and the HOPC-I plasmacytomas, thus indicating cross-reactivity. Spleen cells taken from mice 6 days after the surgical removal of 15-day-old MOPC-104E tumors inhibited the growth of lethal doses of MOPC-104E cells in normal recipients, but no inhibition was observed 2 days after the removal of 18-day-old tumors. Spleen cells from mice bearing MOPC-104E for 13 days enhanced tumor growth. This enhancement was not influenced significantly by the wide dose range (from 10(5) to 3 x 10(7)) of MOPC-104E cells used to initiate tumors in the lymphoid cell donors, although tendency for stronger enhancing potential occurred after low tumor doses. When spleen cells from donors bearing MOPC-104E for 10 days were injected at the constant tumor-lymphocyte ratio of 1:30 with increasing numbers of tumor cells (from 5 x 10(5) to 2 x 10(6)), tumor inhibition occurred at the lowest dose only, while no significant effect was observed at higher tumor cell doses. When a constant dose (5 x 10(5)) of tumor cells was injected with spleen cells from 10-day tumor-bearers at tumor/lymphocyte ratios of 1:10, u:40 and 1:160, a significant tumor inhibition occurred only at the ratio of 1:40. The relevance of the Winn test to the study of immune mechanisms in tumor-bearing hosts is discussed.

Animals↗
PubMed1980

Effector and enhancing lymphoid cells in plasmacytoma-bearing mice. II. Dynamic changes during tumor progression.

The Winn assay was used for the study of effector (tumor-inhibiting) and enhancing (tumor-promoting) lymphoid cells in BALB/c mice bearing MOPC-104E plasmacytomas. Kinetic studies with thymus, lymphnode, spleen and bone-marrow cells revealed that spleen, lymph node and to a lesser extent bone-marrow cells from 7- and 10-day tumor-bearers inhibited MOPC-104E growth, while at day 13 all three cell populations enhanced tumor growth. However, at day 16 strong tumor inhibition was observed again by spleen cells and to a lesser extent by lymph-node cells and thymocytes. Peritoneal cells from normal and tumor-bearing (7 and 10 days) animals enhanced tumor growth significantly. Separation of spleen cells on nylon wool columns showed that at 10 days the effector cells were T lymphocytes, but at a later stage (35 days) a different effector mechanism was present in the spleen. Treatment of MOPC-104E recipients with carrageenan or silica had little influence on tumor growth, but marked tumor inhibition occurred after lethal irradiation and bone-marrow reconstitution. This latter observation, together with the finding that bone-marrow, lymph node and peritoneal cells from normal donors enhanced tumor growth in several experiments, suggests that this plasmacytoma, like hormone-dependent tumors, requires lymphocyte-derived growth factors.

Animals↗
PubMed1988

c-myc expression and transformed phenotypes in hybrid clones between mouse plasmacytoma S194 cells and normal spleen cells or fibroblasts.

Expression of the rearranged c-myc oncogene and transformed phenotypes was investigated in 2 different types of somatic cell hybrid clones between a BALB/c mouse plasmacytoma line (S194) and normal allogeneic spleen cells or fibroblasts. In the parental S194 cells, one allele of the c-myc was rearranged and its 5'-flanking region was partially deleted by recombination with the immunoglobulin C alpha gene. Due to this recombination, S194 cells expressed approximately 20-fold higher than normal spleen or fibroblast levels of c-myc transcripts from the rearranged allele, which are smaller than normal germ-line 2.4-kb c-myc transcripts, but they expressed the same low levels of 2.4-kb c-myc transcripts from the non-rearranged allele as compared with normal spleen cells or fibroblasts. All the hybrid clones retained both the rearranged and the non-rearranged c-myc. The hybrid clones between S194 and normal spleen cells showed transformed phenotypes and expressed the same high levels of rearranged c-myc transcripts and low levels of the non-rearranged c-myc transcripts as the parental S194 cells. On the other hand, the hybrid clones between S194 cells and normal fibroblasts showing non-transformed phenotypes inhibited expression of the rear-ranged c-myc to undetectable levels but expressed the non-rearranged c-myc transcripts at low levels. A hybrid clone between S194 cells and normal fibroblasts showing transformed phenotypes also exhibited the same pattern of c-myc expression as the non-transformed hybrid clones. These results indicate that expression of the rearranged c-myc in S194 mouse plasmacytoma cells is modulated in different ways in different components of cell lineages, although the correlation between the levels of rearranged c-myc transcripts and the transformed phenotypes in the hybrid clones was not absolute.

Animals↗